ACHC trades 11.2% above Wall Street's consensus target of $28.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ACHC achieves its forward estimates and maintains a stable P/E multiple of 21.2x. This scenario reflects the blended consensus of 25 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Acadia Healthcare Company, Inc. (ACHC) has a Wall Street consensus price target of $28.33, based on estimates from 25 covering analysts. With the stock currently trading at $31.92, this represents a potential downside of -11.2%. The company has a market capitalization of $2.94B.
Analyst price targets range from a low of $22.00 to a high of $31.00, representing a 32% spread in expectations. The median target of $30.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ACHC trades at a trailing P/E of -2.6x and forward P/E of 21.2x. Analysts expect EPS to grow +112.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
UHSUniversal Health Services, Inc. | $10.1B | $161.26 | $216.00 | +33.9% | Hold | 6.9x | 43 |
SEMSelect Medical Holdings Corporation | $2.0B | $16.51 | $17.75 | +7.5% | Hold | 13.5x | 14 |
SGRYSurgery Partners, Inc. | $2.2B | $17.17 | $19.33 | +12.6% | Buy | 40.0x | 22 |
BKDBrookdale Senior Living Inc. | $3.7B | $15.42 | $18.75 | +21.6% | Buy | — | 12 |
ENSGThe Ensign Group, Inc. | $10.0B | $170.87 | $222.33 | +30.1% | Buy | 22.6x | 13 |
HCAHCA Healthcare, Inc. | $93.9B | $423.11 | $504.73 | +19.3% | Buy | 14.0x | 46 |
THCTenet Healthcare Corporation | $16.8B | $191.20 | $259.50 | +35.7% | Buy | 10.7x | 32 |
CYHCommunity Health Systems, Inc. | $538M | $3.82 | $2.93 | -23.3% | Hold | — | 37 |
OSCROscar Health, Inc. | $8.1B | $31.12 | $24.20 | -22.2% | Hold | 29.8x | 11 |
CVSCVS Health Corporation | $133.1B | $104.33 | $103.64 | -0.7% | Buy | 14.1x | 41 |
Quick answers to the most common questions about buying ACHC stock.
ACHC's consensus price target is $28.33, -11.2% below the current price of $31.92. The 25 analysts tracking ACHC see downside risk at present valuations.
ACHC has a consensus rating of "Buy" based on 25 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $28.33 implies -11.2% downside from current levels.
ACHC trades at a forward P/E of 21.1769x, representing a moderate valuation. With analysts targeting $28.33 (-11.2% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $31 for ACHC, while the most conservative target is $22. The consensus of $28.33 represents the median expectation. These targets typically reflect 12-month expectations.
ACHC is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ACHC stock forecast based on 25 Wall Street analysts shows a consensus price target of $28.33, with estimates ranging from $22 (bear case) to $31 (bull case). The median consensus rating is "Buy".
ACHC trades at a forward P/E ratio of 21.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on ACHC, with 1 Sell ratings and a price target of $28.33 (-11.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ACHC analyst price targets range from $22 to $31, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.33 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.